What do systematic reviews say?

Insulin injected with a Novolin pen vs insulin injected with a needle or syringe (Different insulin regimens with similar insulin types used within the regimen)

• Different insulin types and regimens for pregnant women with pre‐existing diabetes 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.59 [0.13, 2.63]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 443 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.55 [0.06, 5.12]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.72 [0.91, 3.28]
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir probably leads to lower severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.69 [0.52, 0.92]
  8 studies · 3219 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 495 participants
  Low

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.67 [0.39, 1.17]
  7 studies · 2925 participants
  Moderate

Summary of findings: insulin detemir vs NPH insulin

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.75, 1.21]
  9 studies · 3332 participants
  Moderate

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe hypoglycaemia (n/N) Definition: symptomatic hypoglycaemia… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.67, 1.04]
  9 studies · 2350 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 585 participants
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.08 [0.63, 1.84]
  8 studies · 2229 participants
  Moderate

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin detemir (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.17 [0.81, 1.69]
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 453 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin detemir (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.51, 2.46]
  2 studies · 802 participants
  Low